Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149282 | 0.88 | SLC22A12 (0.43) | SLC22A12SCN9A | |
| SCHEMBL4151856 | 0.88 | KDM4E (0.39) | SCN9A | |
| SCHEMBL4145790 | 0.88 | PIK3CA (0.37) | SCN9A | |
| SCHEMBL4159392 | 0.87 | KDM4E (0.38) | SCN9A | |
| Potassium SCHEMBL4159398 | 0.87 | KDM4E (0.38) | SCN9A | |
| SCHEMBL2535698 | 0.87 | SLC22A12 (0.44) | SLC22A12SCN9A | |
| SCHEMBL2532037 | 0.87 | ALDH1A1 (0.41) | SCN9A | |
| SCHEMBL4146247 | 0.85 | XDH (0.42) | SCN9A | |
| SCHEMBL4146990 | 0.84 | SLC22A12 (0.46) | SLC22A12SCN9AMRGPRX1 | |
| SCHEMBL4152592 | 0.82 | ALDH1A1 (0.52) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3263109-B1 | DRUG FOR PREVENTING AND/OR TREATING DEMENTIA | NAT UNIV CORP TOTTORI UNIV (JP) | 2020-06-17 | — | — | EP | claimed |
| US-20090149452-A1 | XANTHINE OXIDASE INHIBITOR | NIPPON CHEMIPHAR CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1911760-A1 | XANTHINE OXIDASE INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149452-A1 | XANTHINE OXIDASE INHIBITOR | XDH, PNPO, CBR1 | SLC22A12 1556/4885SCN9A 474/4885MRGPRX1 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.